Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Johnson and Johnson
Express Scripts
Dow
Boehringer Ingelheim

Last Updated: February 1, 2023

Details for Patent: 9,636,344


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 9,636,344 protect, and when does it expire?

Patent 9,636,344 protects ALIQOPA and is included in one NDA.

This patent has fifty-three patent family members in forty-two countries.

Summary for Patent: 9,636,344
Title:Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts
Abstract: The present invention relates to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-- c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): ##STR00001## or a tautomer, solvate or hydrate thereof; and to its use for the treatment of non-Hodgkin's lymphoma.
Inventor(s): Peters; Jan-Georg (Solingen, DE), Militzer; Hans-Christian (Odenthal, DE), Muller; Hartwig (Velbert, DE)
Assignee: Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:14/990,350
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,636,344

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Healthcare ALIQOPA copanlisib dihydrochloride POWDER;INTRAVENOUS 209936-001 Sep 14, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,636,344

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
11161111Apr 5, 2011

International Family Members for US Patent 9,636,344

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 3709 See Plans and Pricing
Argentina 085718 See Plans and Pricing
Australia 2012238891 See Plans and Pricing
Brazil 112013025549 See Plans and Pricing
Canada 2832123 See Plans and Pricing
Chile 2013002870 See Plans and Pricing
China 103649091 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Moodys
Colorcon
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.